Sitravatinib, an orally available tyrosine kinase inhibitor (TKI), targets key receptors involved in clear cell renal cell carcinoma (ccRCC) biology including the vascular endothelial growth factor receptor (VEGFR) family, c-MET, and the TAM (TYRO3, AXL, and MER) family. Here, KDR is linked to nonpapillary renal cell carcinoma.